awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E
Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
P2860
Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33658626-9FDB3FD4-41F2-4E15-9E7E-C5E3B207C43E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
98bcf783cbadc1f5e03640840685f538df829331
P2860
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.